Literature DB >> 10611272

Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis.

W S Hlavacek1, C Wofsy, A S Perelson.   

Abstract

Follicular dendritic cells (FDC) provide a reservoir for HIV type 1 (HIV-1) that may reignite infection if highly active antiretroviral therapy (HAART) is withdrawn before virus on FDC is cleared. To estimate the treatment time required to eliminate HIV-1 on FDC, we develop deterministic and stochastic models for the reversible binding of HIV-1 to FDC via ligand-receptor interactions and examine the consequences of reducing the virus available for binding to FDC. Analysis of these models shows that the rate at which HIV-1 dissociates from FDC during HAART is biphasic, with an initial period of rapid decay followed by a period of slower exponential decay. The speed of the slower second stage of dissociation and the treatment time required to eradicate the FDC reservoir of HIV-1 are insensitive to the number of virions bound and their degree of attachment to FDC before treatment. In contrast, the expected time required for dissociation of an individual virion from FDC varies sensitively with the number of ligands attached to the virion that are available to interact with receptors on FDC. Although most virions may dissociate from FDC on the time scale of days to weeks, virions coupled to a higher-than-average number of ligands may persist on FDC for years. This result suggests that HAART may not be able to clear all HIV-1 trapped on FDC and that, even if clearance is possible, years of treatment will be required.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10611272      PMCID: PMC24707          DOI: 10.1073/pnas.96.26.14681

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  In vitro analysis of complement-dependent HIV-1 cell infection using a model system.

Authors:  P Tacnet-Delorme; V Boyer; N M Thielens; J F Hernandez; I Bally; R B Sim; C Desgranges; G J Arlaud
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

2.  Complement activation in the follicular light zone of human lymphoid tissues.

Authors:  M Yamakawa; Y Imai
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

3.  Interaction of iC3b with recombinant isotypic and chimeric forms of CR2.

Authors:  K R Kalli; J M Ahearn; D T Fearon
Journal:  J Immunol       Date:  1991-07-15       Impact factor: 5.422

4.  Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia.

Authors:  J A Tooze; D H Bevan
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

5.  General analysis of receptor-mediated viral attachment to cell surfaces.

Authors:  T J Wickham; R R Granados; H A Wood; D A Hammer; M L Shuler
Journal:  Biophys J       Date:  1990-12       Impact factor: 4.033

6.  Competition between solution and cell surface receptors for ligand. Dissociation of hapten bound to surface antibody in the presence of solution antibody.

Authors:  B Goldstein; R G Posner; D C Torney; J Erickson; D Holowka; B Baird
Journal:  Biophys J       Date:  1989-11       Impact factor: 4.033

7.  Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2).

Authors:  M D Moore; R G DiScipio; N R Cooper; G R Nemerow
Journal:  J Biol Chem       Date:  1989-12-05       Impact factor: 5.157

8.  Quantification of C3dg/Epstein-Barr virus receptors on human B cells and B cell lines.

Authors:  J M Rasmussen; H V Marquart; R Rask; H H Jepsen; S E Svehag
Journal:  Complement       Date:  1988

9.  Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41.

Authors:  C F Ebenbichler; N M Thielens; R Vornhagen; P Marschang; G J Arlaud; M P Dierich
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins.

Authors:  H R Gelderblom; E H Hausmann; M Ozel; G Pauli; M A Koch
Journal:  Virology       Date:  1987-01       Impact factor: 3.616

View more
  20 in total

1.  Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy.

Authors:  W S Hlavacek; N I Stilianakis; D W Notermans; S A Danner; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

2.  Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence.

Authors:  M C Strain; H F Günthard; D V Havlir; C C Ignacio; D M Smith; A J Leigh-Brown; T R Macaranas; R Y Lam; O A Daly; M Fischer; M Opravil; H Levine; L Bacheler; C A Spina; D D Richman; J K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-08       Impact factor: 11.205

3.  Detachment of human immunodeficiency virus type 1 from germinal centers by blocking complement receptor type 2.

Authors:  L Kacani; W M Prodinger; G M Sprinzl; M G Schwendinger; M Spruth; H Stoiber; S Döpper; S Steinhuber; F Steindl; M P Dierich
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Brownian adhesive dynamics (BRAD) for simulating the receptor-mediated binding of viruses.

Authors:  Thomas J English; Daniel A Hammer
Journal:  Biophys J       Date:  2004-06       Impact factor: 4.033

5.  The effect of cellular receptor diffusion on receptor-mediated viral binding using Brownian adhesive dynamics (BRAD) simulations.

Authors:  Thomas J English; Daniel A Hammer
Journal:  Biophys J       Date:  2004-11-19       Impact factor: 4.033

6.  Contribution of follicular dendritic cells to persistent HIV viremia.

Authors:  Jingshan Zhang; Alan S Perelson
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

7.  HIV Eradication: Progress and Challenges.

Authors:  O Prakash; G Pankey
Journal:  Ochsner J       Date:  2001-04

8.  Human immunodeficiency virus type 1 bound to B cells: relationship to virus replicating in CD4+ T cells and circulating in plasma.

Authors:  Angela Malaspina; Susan Moir; David C Nickle; Eileen T Donoghue; Kisani M Ogwaro; Linda A Ehler; Shuying Liu; Jo Ann M Mican; Mark Dybul; Tae-Wook Chun; James I Mullins; Anthony S Fauci
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  HIV infection: what should be considered in approaches for a cure?

Authors:  Jay A Levy; Yves Levy
Journal:  AIDS       Date:  2012-11-13       Impact factor: 4.177

10.  Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues.

Authors:  Rob J De Boer; Ruy M Ribeiro; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2010-09-02       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.